wellbeing news

Pharmacy Therapy: Further Financing for Wiener Phagomed

Credits: XtravaganT –

Vienna biotechnology company PhagoMed Biopharma GmbH has another financing round finished. The company, headquartered in the Vienna Biocentre, deals with it Development of Phage Based Drugs, They use special viruses (phages) for the treatment of multiple resistant bacterial infections. This approach in Fighting the antibiotic crisis now there are new investors an additional EUR 1.5 million the value that the company intends to invest in the further development of three drug candidates. Last year, PhagoMed managed to raise more than 4m euros in private investment and public subsidies and start research activities at the Vienna Biocentre.

Natural antibiotic resistance viruses

PhagoMed works to find solutions to the world's antibiotic crisis, increasing resistance to these powerful drugs. The company develops drugs based on natural viruses that only attack and destroy bacteria known as fage. Because of their ability to target bacteria in a targeted manner, they offer access to new treatment options for multi-drug resistant infections. For example, co-founders of PhagoMed have successfully applied the phage in experimental healing tests in Germany.

The first clinical trial scheduled for 2021

The company claims that it is a particularly promising use of phage for the treatment of infected artificial joints. Hip replacement. Infections of these millions of used prostheses are already difficult to cure because they are often caused by multi-resistant bacteria. They also often form a so-called biofilm coating, which can further reduce the effect of antibiotics. Especially in such infections, phage are a promising alternative because the phages are capable of breaking bacterial biofilms and thus killing bacteria resistant to multiple drugs. One of the three drug candidates identified by the company is the target of this application and is currently being evaluated in animal studies. The company plans to begin clinical trials to treat implant-related infections in 2021.